Polymeric nanoparticle drug delivery technologies for oral delivery applications

Expert Opinion on Drug Delivery

Volumn 12, Issue 9, 2015, Pages 1459-1473

  Pridgen, Eric M ^a   Alexis, Frank ^b   Farokhzad, Omid C ^c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CLEMSON UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

chemotherapy; inflammatory bowel disease; insulin; M cells; mucoadhesives; mucosal vaccinations; oral delivery; polymeric nanoparticles; transcytosis

Indexed keywords

ADHESIVE AGENT; ANTINEOPLASTIC AGENT; BIOMATERIAL; INSULIN; NANOPARTICLE; PEPTIDE; POLYMER; PROTEIN; VACCINE;

CANCER THERAPY; CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; GASTROINTESTINAL TRACT FUNCTION; GIANT CELL; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE ABSORPTION; INTESTINE CELL; NANOTECHNOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; REVIEW; TARGET CELL; TRANSCYTOSIS; VACCINATION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; GASTROINTESTINAL TRACT; INTESTINE; METABOLISM;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; HUMANS; INSULIN; INTESTINES; NANOPARTICLES; POLYMERS;

EID: 84939644520     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.1018175     Document Type: Review

References (135)

1. Aggarwal S. Whats fueling the biotech engine-2012 to 2013. Nat Biotechnol 2014; 32: 32-9
2. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012; 63: 185-98
3. Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012; 4: 128ra39
4. Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-70
5. Lanza GM, Winter PM, Caruthers SD, et al. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomed 2006; 1: 321-9
6. Krol S, Ellis-Behnke R, Marchetti P. Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments. Nanomedicine 2012; 8: S69-76
7. Peppas NA, Kavimandan NJ. Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. Eur J Pharm Sci 2006; 29: 183-97
8. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-15
9. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-58
10. Von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19: 1743-9
11. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006; 21: 132-40
12. Pfeiffer P, Mortensen JP, Bjerregaard B, et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 2006; 42: 2738-43
13. Findlay M, Von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008; 19: 212-22
14. James R, Blanco C, Farina C. Savings in staff time as a result of switching from de Gramont to oral capecitabine for patients with advanced colorectal cancer [abstract 271]. Eur J Cancer 2003; 1 (Suppl 5): S83
15. De Portu S, Mantovani LG, Ravaioli A, et al. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. J Chemother 2010; 22: 125-8
16. Jansman F, Postma M, van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004; 26: 579-89
17. Yabroff K, Warren J, Knopf K, et al. Estimating patient time costs associated with colorectal cancer care. Med Care 2005; 43: 640-8
18. Tortora G. Principles of human anatomy. John Wiley & Sons, Inc; New York: 2005
19. Chen M-C, Sonaje K, Chen K-J, Sung H-W. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011; 32: 9826-38
20. Schenk M, Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol 2008; 22: 391-409
21. Macdonald T, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-5
22. Kararli T. Comparison of the gastrointestinal anatomy, physiology, and bio- chemistry of humans and commonly used laboratory-animals. Biopharm Drug Dispos 1995; 16: 351-80
23. Sood A, Panchagnula R. Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev 2001; 101: 3275-304
24. Ganapathy V, Gupta N, Martindale R. Protein digestion and absorption. Physiology of the gastrointestinal tract. 4th edition. Academic Press; Burlington: 2006
25. Johnson L, Christensen J, Jackson M, et al. Physiology of the gastrointestinal tract. Raven Press; New York: 1987
26. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012; 64: 557-70
27. Lai SK, Wang Y-Y, Wirtz D, Hanes J. Micro-and macrorheology of mucus. Adv Drug Deliv Rev 2009; 61: 86-100
28. Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001; 280: G922-9
29. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev 2009; 61: 75-85
30. Banan A. theta Isoform of protein kinase C alters barrier function in intestinal epithelium through modulation of distinct claudin isotypes: a novel mechanism for regulation of permeability. J Pharmacol Exp Ther 2005; 313: 962-82
31. Mitic LL, Van Itallie CM, Anderson JM. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol 2000; 279: G250-4
32. Stamatovic SM, Keep R, Kunkel S, Andjelkovic A. Potential role of MCP-1 in endothelial cell tight junction 'opening: signaling via Rho and Rho kinase. J Cell Sci 2003; 116: 4615-28
33. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001; 2: 285-93
34. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998; 16: 2557-67
35. Salama N, Eddington N, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 2006; 58: 15-28
36. Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst 2005; 22: 419-64
37. Moore T, Graham E, Mattix B, Alexis F. Biomaterials science: an integrated clinical and engineering approach. 1st edition. Taylor and Francis Group, LLC; Boca Raton, FL: 2012
38. Carino G, Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999; 35: 249-57
39. Lowe PJ, Temple CS. Calcitonin and insulin in isobutylcyanoacrylate nanocap- sules-protection against proteases and effect on intestinal-absorption in rats. J Pharm Pharmacol 1994; 46: 547-52
40. Damge C, Vranckx H, Balschmidt P, Couvreur P. Poly (alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 1997; 86: 1403-9
41. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5: 505-15
42. Valencia PM, Pridgen EM, Rhee M, et al. Microfluidic Platform for Combinatorial Synthesis and Optimization of Targeted Nanoparticles for Cancer Therapy. ACS Nano 2013; 7: 10671-80
43. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012; 2: 3-44
44. Mansour HM, Rhee Y-S, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine 2009; 4: 299-319
45. Tang BC, Dawson M, Lai SK, et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA 2009; 106: 19268-73
46. Smart J. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 2005; 57: 1556-68
47. Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009; 61: 158-71
48. Dünnhaupt S, Barthelmes J, Hombach J, et al. Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa. Int J Pharm 2011; 408: 191-9
49. Makhlof A, Werle M, Tozuka Y, Takeuchi H. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J Control Release 2011; 149: 81-8
50. Chen M-C, Mi F-L, Liao Z-X, et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 2013; 65: 865-79
51. Furtado S, Abramson D, Burrill R, et al. Oral delivery of insulin loaded poly(fumaric-co-sebacic) anhydride microspheres. Int J Pharm 2008; 347: 149-55
52. Boddupalli BM, Mohammed ZNK, Nath RA, Banji D. Mucoadhesive drug delivery system: an overview. J Adv Pharm Technol Res 2010; 1: 381-7
53. Takeuchi H, Thongborisute J, Matsui Y, et al. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv Drug Deliv Rev 2005; 57: 1583-94
54. Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco-and bioadhesion:: tethered structures and site-specific surfaces. J Control Release 2000; 65: 63-71
55. Kotze AF, Luessen HL, De Boer AG, et al. Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. Eur J Pharm Sci 1999; 7: 145-51
56. Sandri G, Bonferoni MC, Rossi S, et al. Insulin-loaded nanoparticles based on N-trimethyl chitosan: in vitro (Caco-2 Model) and ex vivo (excised rat jejunum, duodenum, and ileum) evaluation of penetration enhancement properties. AAPS PharmSciTech 2010; 11: 362-71
57. Krauland AH, Guggi D, Bernkop-Schnürch A. Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats. J Control Release 2004; 95: 547-55
58. Bravo-Osuna I, Vauthier C, Farabollini A, et al. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 2007; 28: 2233-43
59. Sonaje K, Lin Y-H, Juang J-H, et al. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009; 30: 2329-39
60. Adson A, Burton PS, Raub TJ, et al. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J Pharm Sci 1995; 84: 1197-204
61. Sonaje K, Chuang E-Y, Lin K-J, et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 2012; 9: 1271-9
62. Sonaje K, Lin K-J, Wey S-P, et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-Responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010; 31: 6849-58
63. Yeh T-H, Hsu L-W, Tseng MT, et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 2011; 32: 6164-73
64. Sonaje K, Lin K-J, Tseng MT, et al. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 2011; 32: 8712-21
65. Cano-Cebrian MJ, Zornoza T, Granero L, Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv 2005; 2: 9-22
66. Bakhru SH, Furtado S, Morello AP, Mathiowitz E. Oral delivery of proteins by biodegradable nanoparticles. Adv Drug Deliv Rev 2013; 65: 811-21
67. Jang MH, Kweon M-N, Iwatani K, et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc Natl Acad Sci USA 2004; 101: 6110-15
68. Eldridge JH, Hammond CJ, Meulbroek JA, et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyers patches. J Control Release 1990; 11: 205-14
69. Des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006; 116: 1-27
70. Des Rieux A, Fievez V, Théate I, et al. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm Sci 2007; 30: 380-91
71. Roger E, Lagarce F, Garcion E, Benoit J-P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomed 2010; 5: 287-306
72. Slütter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J Drug Target 2008; 16: 1-17
73. Clark M, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 2001; 50: 81-106
74. Porta C, James PS, Phillips AD, et al. Confocal analysis of fluorescent bead uptake by mouse Peyers patch follicle-associated M cells. Exp Physiol 1992; 77: 929-32
75. Brayden DJ. Oral vaccination in man using antigens in particles: current status. Eur J Pharm Sci 2001; 14: 183-9
76. Kammona O, Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release 2012; 161: 781-94
77. De Jesus M, Ostroff GR, Levitz SM, et al. A population of Langerin-positive dendritic cells in murine Peyers patches involved in sampling β-glucan microparticles. PLoS One 2014; 9: e91002
78. Khafagy E-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007; 59: 1521-46
79. Fievez V, Plapied L, des Rieux A, et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm 2009; 73: 16-24
80. Jepson MA, Clark MA. Studying M cells and their role in infection. Trends Microbiol 1998; 6: 359-65
81. Miller H, Zhang J, KuoLee R, et al. Intestinal M cells: the fallible sentinels? World J Gastroenterol 2007; 13: 1477
82. Pappo J, Ermak TH, Steger HJ. Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyers patch M cells. Immunology 1991; 73: 277
83. Jepson MA, Clark MA, Foster N, et al. Targeting to intestinal M cells. J Anat 1996; 189: 507
84. Sass W, Dreyer HP, Seifert J. Rapid insorption of small particles in the gut. Am J Gastroenterol 1990; 85: 255-60
85. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996; 13: 1838-45
86. Desai MP, Lab V, Walter E, et al. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997; 14: 1568-73
87. Gabor F, Schwarzbauer A, Wirth M. Lectin-mediated drug delivery: binding and uptake of BSA-WGA conjugates using the Caco-2 model. Int J Pharm 2002; 237: 227-39
88. Gabor F, Wirth M, Jurkovich B, et al. Lectin-mediated bioadhesion: proteolytic stability and binding-characteristics of wheat germ agglutinin and Solanum tuberosum lectin on Caco-2, HT-29 and human colonocytes. J Control Release 1997; 49: 27-37
89. Kilpatrick DC, Pusztai A, Grant G, et al. Tomato lectin resists digestion in the mammalian alimentary canal and binds to intestinal villi without deleterious effects. FEBS Lett 1985; 185: 299-305
90. Hussain N, Jani PU, Florence AT. Enhanced oral uptake of tomato lectin- conjugated nanoparticles in the rat. Pharm Res 1997; 14: 613-18
91. Weissenboeck A, Bogner E, Wirth M, Gabor F. Binding and uptake of wheat germ agglutinin-grafted PLGA-nanospheres by caco-2 monolayers. Pharm Res 2004; 21: 1917-23
92. Lochner N, Pittner F, Wirth M, Gabor F. Wheat germ agglutinin binds to the epidermal growth factor receptor of artificial Caco-2 membranes as detected by silver nanoparticle enhanced fluorescence. Pharm Res 2003; 20: 833-9
93. Clark M, Hirst BH, Jepson MA. Lectin-mediated mucosal delivery of drugs and microparticles. Adv Drug Deliv Rev 2000; 43: 207-23
94. Bies C, Lehr C-M, Woodley JF. Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev 2004; 56: 425-35
95. Roger E, Kalscheuer S, Kirtane A, et al. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol Pharm 2012; 9: 2103-10
96. Petrus AK, Fairchild TJ, Doyle RP. Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs. Angew Chem Int Ed 2009; 48: 1022-8
97. Fowler R, Vllasaliu D, Trillo FF, et al. Nanoparticle transport in epithelial cells: pathway switching through bioconjugation. Small 2013; 9: 3282-94
98. Chalasani KB, Russell-Jones GJ, et al. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 2007; 122: 141-50
99. Chalasani KB, Russell-Jones GJ, Yandrapu SK, et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release 2007; 117: 421-9
100. Yoshida M, Claypool SM, Wagner JS, et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004; 20: 769-83
101. Claypool SM, Dickinson BL, Wagner JS, et al. Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fcgamma-receptor. Mol Biol Cell 2004; 15: 1746-59
102. Israel EJ, Taylor S, Wu Z, et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 1997; 92: 69-74
103. Raghavan M, Gastinel LN, Bjorkman PJ. The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. Biochemistry (Mosc) 1993; 32: 8654-60
104. Lalezari D. Gastrointestinal pH profile in subjects with irritable bowel syndrome. Ann Gastroenterol 2012; 25: 333
105. Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. Nat Rev Mol Cell Biol 2010; 11: 50-61
106. Pridgen EM, Alexis F, Kuo TT, et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci Transl Med 2013; 5: 213ra167
107. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005; 28: 1240-4
108. Oostendorp RL, Huitema A, Rosing H, et al. Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors. Clin Cancer Res 2009; 15: 4228-33
109. Attili-Qadri S, Karra N, Nemirovski A, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci USA 2013; 110: 17498-503
110. Bisht S, Feldmann G, Koorstra J-BM, et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther 2008; 7: 3878-88
111. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004; 6: 510-17
112. Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol 2002; 13: S92-6
113. Brogden RN, Heel RC. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs 1987; 34: 350-71
114. Jongen PJ, Hengstman G, Hupperts R, et al. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study). BMC Neurol 2011; 11: 40
115. Kondiah PPD, Tomar LK, Tyagi C, et al. A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis. Int J Pharm 2013; 456: 459-72
116. Guggi D, Kast CE, Bernkop-Schnürch A. In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm Res 2003; 20: 1989-94
117. Cetin M, Aktas MS, Vural I, Ozturk M. Salmon calcitonin-loaded Eudragit® and Eudragit®-PLGA nanoparticles: in vitro and in vivo evaluation. J Microencapsul 2012; 29: 156-66
118. Italia JL, Bhardwaj V, Ravi Kumar MNV. Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. Drug Discov Today 2006; 11: 846-54
119. Italia JL, Bhatt DK, Bhardwaj V, et al. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®. J Control Release 2007; 119: 197-206
120. Lamprecht A. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 2005; 315: 196-202
121. Nakase H, Okazaki K, Tabata Y, et al. An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. J Pharmacol Exp Ther 2001; 297: 1122-8
122. Wachsmann P, Lamprecht A. Polymeric nanoparticles for the selective therapy of inflammatory bowel disease. Methods Enzymol 2012; 508: 377-97
123. Lamprecht A, Schäfer U, Lehr C-M. Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 2001; 18: 788-93
124. Lamprecht A, Ubrich N, Yamamoto H, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001; 299: 775-81
125. Pertuit D, Moulari B, Betz T, et al. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release 2007; 123: 211-18
126. Laroui H, Viennois E, Xiao B, et al. Fab-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release 2014; 186: 41-53
127. Moulari B, Béduneau A, Pellequer Y, Lamprecht A. Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J Control Release 2014; 188: 9-17
128. Wilson DS, Dalmasso G, Wang L, et al. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 2010; 9: 923-8
129. Roy K, Mao H-Q, Huang S-K, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-91
130. Chew JL, Wolfowicz CB, Mao H-Q, et al. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine 2003; 21: 2720-9
131. Li GP, Liu ZG, Liao B, Zhong NS. Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell Mol Immunol 2009; 6: 45-50
132. Eldridge JH, Meulbroek JA, Staas JK, et al. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 1989; 251: 191-202
133. Zhu Q, Talton J, Zhang G, et al. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med 2012; 18: 1291-6
134. Gebert A. The role of M cells in the protection of mucosal membranes. Histochem Cell Biol 1997; 108: 455-70
135. Martín MG, Wu SV, Walsh JH. Ontogenetic development and distribution of antibody transport and Fc receptor mRNA expression in rat intestine. Dig Dis Sci 1997; 42: 1062-9